Evicenter
MarkdownMedical informationP&T meetings
Ifezuntirgene inilparvovec (AMT-130)

Huntington's disease

Manufacturer
uniQure
Launch
Not announced
Last updated
291 sources

Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care

Limitations of current therapies

7 evidence topics · 21 sources

Summary

In a review of disease-modifying interventions, none of the pharmacological interventions proved effective as a disease-modifying therapy for HD, and the Huntington's Disease Society of America states that there is currently no cure or treatment that can halt, slow, or reverse progression of the disease.

  • Chorea: in a review of 22 trials (1254 participants), only tetrabenazine showed clear efficacy for the control of chorea. An evidence-based review concluded that the data support only the use of VMAT2 inhibitors for specific motor symptoms. The prescribing information for tetrabenazine, deutetrabenazine, and valbenazine states that each can increase the risk of depression and suicidal thoughts and behavior in patients with HD, and tetrabenazine is contraindicated in patients who are actively suicidal or have untreated or inadequately treated depression. In the 12-week placebo-controlled tetrabenazine study, 10 of 54 patients (19%) reported depression or worsening depression compared with none of 30 placebo-treated patients; Total Chorea Scores returned to baseline at the Week 13 follow-up, 1 week after discontinuation, and measures of functional capacity and cognition showed no difference from placebo. The valbenazine prescribing information states that drug-induced parkinsonism can cause more functional disability than untreated chorea for some patients. Side effects of neuroleptics include apathy, sedation, akathisia, worsening of voluntary motor control, tardive dyskinesia, and neuroleptic malignant syndrome. One publication states that pharmacologic treatment of chorea remains underutilized in clinical practice.
  • Psychiatric symptoms: the evidence-based review found no eligible evidence to support specific treatments for depression, psychosis, irritability, apathy, or suicidality. A review of fifteen articles concluded that convincing evidence to guide practice is lacking, and one guideline states that its recommendations on mental health problems are based on expert opinion.
  • Cognitive symptoms: one guideline recommends no pharmacological treatment for cognitive symptoms.
  • Nonpharmacological care: the evidence-based review found no eligible evidence to support physiotherapy, occupational therapy, exercise, dietary, or surgical treatments.
  • Evidence base: among 376 therapeutic studies conducted between 1965 and 2015, the authors of that guideline found one grade A study.
Summary: investigational therapies and regulatory history of ifezuntirgene inilparvovec
  • Tominersen: in GENERATION HD1, treatment was stopped in March 2021 on the basis of an independent data monitoring committee's benefit-risk assessment, and the cUHDRS change at week 69 in the every-8-week group was significantly worse than placebo (−0.54 points, adjusted P=0.001). In GENERATION HD2, reductions in mHTT protein and NfL in 301 participants did not translate into a meaningful improvement in clinical outcomes, and Roche discontinued clinical development of tominersen.
  • Pridopidine: the primary and key secondary endpoints (change in TFC and cUHDRS at week 65) of the phase III PROOF-HD study were not met in the overall population. In its questions and answers on the withdrawal of the marketing authorisation application for pridopidine (Nurzigma), the European Medicines Agency noted that the validity and relevance of the subgroup results in patients not treated with antidopaminergic medicines had not been demonstrated.
  • Ifezuntirgene inilparvovec (AMT-130): the sponsor stated at its BLA submission that there are currently no approved therapies to delay the onset or slow the progression of HD. The sponsor reported that, at an RMAT Type B meeting, the FDA agreed that Phase I/II data compared with a natural history external control may serve as the primary basis for a BLA submission under the Accelerated Approval pathway. After a pre-BLA meeting held on October 29, 2025, the FDA conveyed that the Phase I/II data were currently unlikely to provide the primary evidence to support a BLA submission. Final minutes of a Type A meeting held on January 30, 2026 stated that the FDA could not agree that the Phase I/II data compared with an external control were sufficient, and the FDA strongly recommended a prospective, randomized, double-blind, sham surgery-controlled study. After a subsequent Type B meeting, the FDA communicated that the 3-year analysis would be acceptable as the primary basis of a BLA for accelerated approval. The third quarter 2026 Form 10-Q states both that the submission was announced in September 2026 and that the BLA was submitted in August 2026 and accepted for review in October 2026; it reports the acceptance as announced on November 2, 2026. The application was granted Priority Review with a PDUFA target action date of May 1, 2027, and the 48-month topline results were not part of the BLA.